和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

盘前交易 12-19 07:46:55 EST

14.48

-0.38

-2.56%

最高14.90	最低14.32	成交量9.41万
今开14.72	昨收14.86	日振幅3.90%
总市值24.75亿	流通市值14.95亿	总股本1.71亿
成交额136.82万	换手率0.09%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":14.48,"timestamp":1734555600000,"preClose":14.86,"halted":0,"volume":94074,"delay":0,"floatShares":103214866,"shares":170936284,"eps":-0.245665,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.38,"latestTime":"12-19 07:46:55 EST","open":14.72,"high":14.9,"low":14.32,"amount":1368205.764894,"amplitude":0.039031,"askPrice":15.94,"askSize":100,"bidPrice":13.17,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.245665,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734618600000},"adr":1,"listingDate":1458187200000,"adjPreClose":14.48,"adrRate":5,"postHourTrading":{"tag":"盘后","latestPrice":14.48,"preClose":14.48,"latestTime":"18:09 EST","volume":751,"amount":10856.37,"timestamp":1734563374477},"volumeRatio":0.9968607300371222,"impliedVol":0.5653,"impliedVolPercentile":0.4024},"requestUrl":"/m/hq/s/HCM/wiki","defaultTab":"wiki","newsList":[{"id":"2492784160","title":"南向资金12月18日净卖出和黄医药303.07万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492784160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492784160?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571805,"startTime":"0","endTime":"0","summary":"12月18日，南向资金减持和黄医药303.07万股连续5日减持。截止当日收盘，港股通共持有和黄医药19047.22万股，占流通股21.84%。港股通减持金额前五个股分别为美团-W、腾讯控股、药明生物、比亚迪电子、吉利汽车。和黄医药近5个交易日下跌9.96%，港股通累计减持693.85万股；近20个交易日下跌17.38%，港股通累计增持433.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093010ab832692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093010ab832692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","HCM","BK1191","00013","BK1588"],"gpt_icon":0},{"id":"2492346130","title":"和黄医药(US ADR)下跌2.09%，报14.55美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492346130","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492346130?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:04","pubTimestamp":1734548660,"startTime":"0","endTime":"0","summary":"12月19日，和黄医药(US ADR)(HCM)盘中下跌2.09%，截至03:04，报14.55美元/股，成交46.28万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19030446565844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4007","BK1588","BK4588","00013","BK1587","BK1191","BK4531","HCM","BK4585"],"gpt_icon":0},{"id":"2492710756","title":"南向资金12月16日净卖出和黄医药185.41万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492710756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492710756?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399005,"startTime":"0","endTime":"0","summary":"12月16日，南向资金减持和黄医药185.41万股连续3日减持。截止当日收盘，港股通共持有和黄医药19401.34万股，占流通股22.24%。和黄医药近5个交易日下跌12.83%，港股通累计减持258.05万股；近20个交易日下跌11.01%，港股通累计增持913.32万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093011ab7dbc6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093011ab7dbc6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","BK1587","00013","HCM"],"gpt_icon":0},{"id":"2491763104","title":"和黄医药(00013)下跌5.09%，报23.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491763104","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491763104?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:45","pubTimestamp":1734327909,"startTime":"0","endTime":"0","summary":"12月16日，和黄医药(00013)盘中下跌5.09%，截至13:45，报23.3元/股，成交6865.1万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16134546412704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","BK1588","BK4588","00013","BK1587","BK1191","BK4531","HCM","BK4585"],"gpt_icon":0},{"id":"2491686967","title":"和黄医药12月13日遭南向资金减持124.97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491686967","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491686967?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312605,"startTime":"0","endTime":"0","summary":"12月13日，南向资金减持和黄医药124.97万股。截止当日收盘，港股通共持有和黄医药19586.75万股，占流通股22.46%。和黄医药近5个交易日下跌7.88%，港股通累计减持67.84万股；近20个交易日下跌7.53%，港股通累计增持1220.20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093017a1f1a628&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093017a1f1a628&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","HCM","BK1587","BK1588","BK1191"],"gpt_icon":0},{"id":"2491364296","title":"和黄医药(00013)：继FRUZAQLA®在欧洲首次纳入医保将获得来自武田的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2491364296","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491364296?lang=zh_cn&edition=full","pubTime":"2024-12-13 08:27","pubTimestamp":1734049650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，该公司今日宣布将收到一笔来自合作伙伴武田 的1000万美元的里程碑付款。武田于2024年12月在西班牙取得FRUZAQLA用于治疗经治的转移性结直肠癌患者获纳入公共医疗保障范围的建议，这是在欧洲取得的首个纳入公共医疗保障范围的建议。结直肠癌是欧洲第二大癌症相关死亡原因。FRUZAQLA于2024年6月在欧盟取得欧盟委员会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1191","BK4531","BK4007","BK1588","HCM","BK4585","00013","BK1587"],"gpt_icon":0},{"id":"2490387385","title":"和黄医药(US ADR)下跌2.03%，报15.95美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490387385","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490387385?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:51","pubTimestamp":1734015111,"startTime":"0","endTime":"0","summary":"12月12日，和黄医药(US ADR)(HCM)盘中下跌2.03%，截至22:51，报15.95美元/股，成交38.78万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/12225146338207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4531","BK4585","BK1587","BK1191","BK1588","BK4007","BK4588","HCM","00013"],"gpt_icon":0},{"id":"2490825300","title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®的联合疗法在中国获纳入突破性治疗品种用于治疗EGFR抑制剂治疗后疾病进展的特定的肺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825300","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490825300?lang=zh_cn&edition=full","pubTime":"2024-12-12 12:18","pubTimestamp":1733977099,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，中国国家药品监督管理局药品审评中心将沃瑞沙和泰瑞沙纳入突破性治疗药物品种，用于治疗伴有MET扩增的接受表皮生长因子受体抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者 。获纳入突破性治疗品种的药物可在提交新药上市申请时提出附条件批准申请和优先审评审批申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®的联合疗法在中国获纳入突破性治疗品种用于治疗EGFR抑制剂治疗后疾病进展的特定的肺癌患者","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HCM","BK1587","BK1191","00013","BK4531","BK1588","BK4585","BK4007"],"gpt_icon":0},{"id":"2490457908","title":"南向资金12月11日净买入和黄医药59.65万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2490457908","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490457908?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:30","pubTimestamp":1733967006,"startTime":"0","endTime":"0","summary":"12月11日, 南向资金增持和黄医药59.65万股，连续3日增持。截止当日收盘，港股通共持有和黄医药19741.07万股，占流通股22.64%。和黄医药近5个交易日下跌4.66%，港股通累计增持15.09万股；近20个交易日下跌5.19%，港股通累计增持1558.30万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093012ab70ff5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093012ab70ff5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK4007","BK4585","BK4588","BK4531","HCM"],"gpt_icon":0},{"id":"2490184571","title":"广发证券：维持和黄医药(00013)“买入”评级 合理价值41.35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490184571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490184571?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:16","pubTimestamp":1733966186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，广发证券发布研究报告称，维持和黄医药“买入”评级，预计24-26年归母净利润分别为0.05、0.20、0.74亿美元，通过DCF法得到公司合理价值为41.35港元/股。此次获批验证了呋喹替尼联合其他药物尤其是免疫检查点抑制剂的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013","01776"],"gpt_icon":0},{"id":"2490776450","title":"和黄医药盘中异动 股价大涨5.10%报17.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490776450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490776450?lang=zh_cn&edition=full","pubTime":"2024-12-09 23:07","pubTimestamp":1733756850,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日23时07分，和黄医药股票出现波动，股价大幅拉升5.10%。截至发稿，该股报17.93美元/股，成交量2.1226万股，换手率0.01%，振幅3.75%。和黄医药股票所在的制药行业中，整体跌幅为1.01%。其相关个股中，苏轩堂、Gelteq Limited、Scilex Holding Company涨幅较大，苏轩堂、大自然药业、Bioage Labs, Inc.较为活跃，换手率分别为496.66%、187.58%、14.42%，振幅较大的相关个股有苏轩堂、Sunshine Biopharma Inc.、Quantum Biopharma Ltd.，振幅分别为14.86%、11.72%、11.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120923073095e86a3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120923073095e86a3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4531","HCM","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2489290123","title":"和黄医药首席医学官石明：出海带动明星抗癌药销量大增，目标明年实现自给自足","url":"https://stock-news.laohu8.com/highlight/detail?id=2489290123","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489290123?lang=zh_cn&edition=full","pubTime":"2024-12-07 11:13","pubTimestamp":1733541184,"startTime":"0","endTime":"0","summary":"本文来源：时代周报 作者：杜苏敏在与跨国药企武田制药就核心产品呋喹替尼达成合作后，创新药企和黄医药（00013.HK）进入快速发展期。呋喹替尼是和黄医药自主研发的首款抗癌新药，作为一款喹唑啉类小分子血管生成抑制剂，其主要作用靶点是VEGFR激酶家族（VEGFR1、2和3），用于治疗晚期结直肠癌。2018年，呋喹替尼（国内商品...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OuWmzr-TMkJ8E6SEDoKoCUkYy682mGLuSu907f-H_OO_EAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OuWmzr-TMkJ8E6SEDoKoCUkYy682mGLuSu907f-H_OO_EAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241207A031BK00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241207A031BK00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["HCM","BK4588","BK1587","BK1191","BK4007","BK4531","BK4585","00013","BK1588"],"gpt_icon":0},{"id":"2488150279","title":"和黄医药与信达生物宣布爱优特®（呋喹替尼/fruquintinib）联合达伯舒® （信迪利单抗注射液/sintilimab injection）获中国国家药监局附条件批准用于治疗晚期子宫内膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2488150279","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488150279?lang=zh_cn&edition=full","pubTime":"2024-12-03 19:39","pubTimestamp":1733225940,"startTime":"0","endTime":"0","summary":"此次获批标志着呋喹替尼与领先的免疫检查点抑制剂联合疗法的首个监管注册批准。此次国家药监局的附条件批准是基于FRUSICA-1研究注册阶段的数据支持。不良事件与同类免疫联合抗血管生成治疗的报道一致。\" 2023年7月，呋喹替尼与信迪利单抗的联合疗法获国家药监局纳入突破性治疗品种用于此项潜在适应症。其于2020年1月获纳入中国国家医保药品目录。自呋喹替尼在中国上市以来已惠及超过10万名结直肠癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4570528_ZH70528_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","00013","HCM","BK1587","BK1588","BK4585","BK4531","BK1191","BK4007"],"gpt_icon":0},{"id":"2488994920","title":"和黄医药(00013)与信达生物(01801)联合宣布爱优特®联合达伯舒®获中国国家药监局附条件批准用于治疗晚期子宫内膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2488994920","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488994920?lang=zh_cn&edition=full","pubTime":"2024-12-03 18:11","pubTimestamp":1733220699,"startTime":"0","endTime":"0","summary":"和黄医药与信达生物联合公布，爱优特与达伯舒联合疗法用于治疗既往系统性抗肿瘤治疗后失败且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整的子宫内膜癌患者的新药上市申请在中国获附条件批准。此次国家药监局的附条件批准是基于 FRUSICA-1 研究注册阶段的数据支持。2023 年 7 月，呋喹替尼与信迪利单抗的联合疗法获国家药监局纳入突破性治疗品种用于此项潜在适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK4588","01801","LU1969619763.USD","00013","BK1583","LU2328871848.SGD","HCM","BK1587","BK1588","BK4007","BK4585","BK4531","BK1191","BK1161","BK1589"],"gpt_icon":0},{"id":"2488686699","title":"【券商聚焦】国信证券维持和黄医药(00013)“优于大市”评级 指公司的临床开发与商业化均取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2488686699","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488686699?lang=zh_cn&edition=full","pubTime":"2024-12-03 13:56","pubTimestamp":1733205377,"startTime":"0","endTime":"0","summary":"公司的临床开发与商业化均取得进展，该行维持盈利预测，预计2024-26年公司的营收为6.59/8.18/9.32亿美元，同比增长-21.3%/24.0%/14.0%，归母净利润为-0.12/0.61/1.08亿美元，维持“优于大市”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002736","00013","HCM"],"gpt_icon":0},{"id":"2488126931","title":"港股异动 | 和黄医药(00013)涨近3% 赛沃替尼美国报产在即 呋喹替尼海外销售快速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2488126931","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488126931?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:07","pubTimestamp":1733191652,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药涨近3%，截至发稿，涨2.02%，报27.8港元，成交额1754.86万港元。东吴证券发布研报指出，赛沃替尼今年医保谈判未降价，美国即将申报上市。国信证券认为，和黄医药的核心产品呋喹替尼正处于海外销售快速放量期，赛沃替尼也有望向FDA递交上市申请，索乐匹尼布临床数据优秀，预计将于2025年获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4531","BK4588","BK1191","BK1588","BK4585","00013","HCM","BK1587"],"gpt_icon":0},{"id":"2487504755","title":"和黄医药盘中异动 早盘股价大跌8.36%报16.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487504755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487504755?lang=zh_cn&edition=full","pubTime":"2024-11-29 22:32","pubTimestamp":1732890745,"startTime":"0","endTime":"0","summary":"北京时间2024年11月29日22时32分，和黄医药股票出现波动，股价急速下跌8.36%。截至发稿，该股报16.89美元/股，成交量5102股，换手率0.00%，振幅1.36%。和黄医药股票所在的制药行业中，整体涨幅为0.19%。其相关个股中，博美集团、Citius Oncology, Inc.、苏轩堂涨幅较大，Painreform Ltd.、Sunshine Biopharma Inc.、Akanda Corp.较为活跃，换手率分别为503.69%、0.71%、0.59%，振幅较大的相关个股有博美集团、Painreform Ltd.、Medicus Pharma Ltd.，振幅分别为12.38%、12.00%、11.81%。该公司经营两个可报告的肿瘤学/免疫学部门和其他风险投资部门。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223225a25f7524&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223225a25f7524&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4531","BK4588","BK4585","HCM"],"gpt_icon":0},{"id":"2487722374","title":"和黄医药(00013)下跌5.03%，报26.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487722374","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487722374?lang=zh_cn&edition=full","pubTime":"2024-11-29 10:12","pubTimestamp":1732846363,"startTime":"0","endTime":"0","summary":"11月29日，和黄医药(00013)盘中下跌5.03%，截至10:12，报26.45元/股，成交5874.17万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/29101245826132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4588","HCM","BK1587","BK1191","00013","BK4531","BK1588","BK4585","BK4007"],"gpt_icon":0},{"id":"2486396325","title":"和黄医药(00013)：沃瑞沙® (赛沃替尼/savolitinib) 按现行条款成功续约中国国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486396325","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486396325?lang=zh_cn&edition=full","pubTime":"2024-11-28 18:09","pubTimestamp":1732788551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，经过与中国国家医疗保障局的医保续约，沃瑞沙将继续获纳入自2025年1月1日起生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》，并维持与现行两年期协议相同的条款。其于2021年6月在中国获附条件批准，用于治疗特定的MET外显子14跳跃突变的非小细胞肺癌患者。中国肺癌患者人数占全世界肺癌患者总数的三分之一以上。沃瑞沙于2023年3月1日首次获纳入医保药品目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","BK4588","BK1588","00013","HCM","BK4007","BK4531","BK1587"],"gpt_icon":0},{"id":"2486878288","title":"和黄医药盘中异动 早盘快速上涨5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486878288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486878288?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:32","pubTimestamp":1732717928,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时32分，和黄医药股票出现波动，股价快速拉升5.98%。截至发稿，该股报18.42美元/股，成交量2758股，换手率0.00%，振幅0.75%。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和黄医药股票所在的制药行业中，整体跌幅为0.35%。该公司经营两个可报告的肿瘤学/免疫学部门和其他风险投资部门。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223208abe36a13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223208abe36a13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4531","BK4588","HCM","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.1106},{"period":"1month","weight":-0.1396},{"period":"3month","weight":-0.1386},{"period":"6month","weight":-0.1924},{"period":"1year","weight":-0.1897},{"period":"ytd","weight":-0.2004}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.04629},{"month":2,"riseRate":0.375,"avgChangeRate":-0.008286},{"month":3,"riseRate":0.375,"avgChangeRate":-0.005299},{"month":4,"riseRate":0.555556,"avgChangeRate":0.042359},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.070144},{"month":6,"riseRate":0.666667,"avgChangeRate":0.076759},{"month":7,"riseRate":0.555556,"avgChangeRate":0.038822},{"month":8,"riseRate":0.444444,"avgChangeRate":0.020061},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.025072},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.0009},{"month":11,"riseRate":0.777778,"avgChangeRate":0.124286},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.009912}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}